Characterization of a non-addictive small molecule therapeutics for the management of non-cancer pain period of performance september 18, 2020 - september 17, 2022
Ended Awarded Last action
- Contract number
- 75N95020F00002
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,327,263
Award facts
- Contract value 60% obligated
-
- $2,327,263.00 Current, with exercised options
- $3,893,053.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $120,890 | |
| Supplemental Agreement for work within scope | $168,560 | |
| Supplemental Agreement for work within scope | $798,239 | |
| Supplemental Agreement for work within scope | $369,809 | |
| Exercise an Option | $269,269 | |
| Exercise an Option | $223,635 | |
| Exercise an Option | $32,212 | |
| Original award | $344,649 |
About this award
This is a $3,893,053.00 cost-plus-fixed-fee delivery order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to the Lovelace Biomedical Research Institute, a not-for-profit organization. The contract is for the characterization of a non-addictive small molecule therapeutic for the management of non-cancer pain, with a period of performance from September 18, 2020 to September 17, 2022, and an ultimate completion date of April 28, 2025. This contract is not set aside and is part of a larger contracting vehicle, though details on the specific vehicle are not provided. Lovelace Biomedical Research Institute is an experienced preclinical contract research organization that supports federal agencies like the National Institutes of Health, Department of Defense, and Department of Health and Human Services with a range of animal studies and product development services.
Quick answers
Who was awarded contract 75N95020F00002?
75N95020F00002 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 18, 2020.
How much is contract 75N95020F00002 worth?
The government has obligated $2,327,263 on 75N95020F00002. Its potential value, with all options, is $3,893,053.
Which agency awarded contract 75N95020F00002?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95020F00002, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95020F00002 an order under another contract?
Yes. 75N95020F00002 is a delivery order under 75N95019D00012, an indefinite delivery contract.
Was contract 75N95020F00002 competed?
The extent of competition for 75N95020F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award